| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-07-14 | Peregrine Pharmaceuticals (USA - CA) University of Texas (UT) Southwestern Medical Center (USA - TX) | exosome technology with potential application as a blood test to detect or monitor cancer | licensing |
Cancer - Oncology - Diagnostic | Licensing agreement | |
| 2016-07-13 | Redhill Biopharma (Israel) National Institute of Allergy and Infectious Diseases (NIAID) (USA) | Ebola fever | R&D collaboration |
Infectious diseases | R&D agreement | |
| 2016-07-13 | Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) | BI 836845 and abemaciclib (LY2835219) | hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-07-12 | Bayer Healthcare (Germany) X-Chem (USA - MA) | novel small molecule therapeutics | R&D |
Technology - Services | R&D agreement | |
| 2016-07-12 | Amicus Therapeutics (USA - NJ) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-07-12 | Cambrex (USA - NJ) | opening of new premises | Technology - Services | Opening of new premises | ||
| 2016-07-12 | Wave LIfe Sciences (USA - MA) | head of neurology franchise | nomination | Rare diseases - Genetic diseases - Neurological diseases | Nomination | |
| 2016-07-11 | Avexis (USA - IL) | nomination |
Rare diseases - Genetic diseases - Neurological diseases | Nomination | ||
| 2016-07-11 | Angionetics (USA - CA) Huapont Life Sciences Affiliate (China) | Generx® [Ad5FGF-4] angiogenic gene therapy product candidat | refractory angina due to ischemic heart disease | licensing commercialisation |
Cardiovascular diseases | Licensing agreement |
| 2016-07-11 | Theradiag (France) | nomination |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Diagnostic | Nomination | ||
| 2016-07-11 | Ipsen (France) | nomination |
Nomination | |||
| 2016-07-11 | Kiadis Pharma (The Netherlands) The Leukemia & Lymphoma Society | ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2016-07-11 | Kiadis Pharma (The Netherlands) The Leukemia & Lymphoma Society | ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2016-07-11 | Celyad (Belgium) Ono Pharmaceutical (Japan) | NKR-2 T-cell immunotherapy | development - licensing - commercialisation | Licensing agreement | ||
| 2016-07-08 | AstraZeneca (UK) Fibrogen (USA - CA) | roxadustat (FG-4592) | anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD) | development |
Kidney diseases - Renal diseases | Milestone |
| 2016-07-08 | BioInvent (Sweden) Alligator Bioscience (Sweden) | ADC-1015 | development production manufacturing |
Development agreement | ||
| 2016-07-08 | Horama (France) | nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | ||
| 2016-07-07 | Onxeo (France) Royal College of Surgeons in Ireland (RCSI) (Ireland) | Beleodaq® derivatives | R&D collaboration |
Cancer - Oncology | R&D agreement | |
| 2016-07-07 | Armagen (USA - CA) Rett Syndrome Research Trust (USA - CT) | MeCP2 protein | Rett syndrome | collaboration |
Rare diseases - Genetic diseases - Neurological diseases | Collaboration agreement |
| 2016-07-06 | RedHill Biopharma (Israel) IntelGenx (Canada) Grupo JUSTE (Spain) | Rizaport® (formerly RHB-103 - oral thin film formulation of rizatriptan) | acute migraines | commercialisation |
CNS diseases | Commercialisation agreement |
